Search results
-
J&J deal cements Ambrx’s transformation
… cohorts 4-8 the confirmed ORR was 22%. Source: ESMO 2023. Any lingering doubts now become …
- 01/10/2024 - 14:31 -
Merck’s latest move is in bispecifics
… toxicity. In a phase 1/2 study presented at ESMO 2023 HPN328 produced a confirmed response rate of 32% … house Ph1 +/- Keytruda in solid tumours ; data at ESMO 2023 Not yet given Source: Mizuho note, …
- 06/19/2024 - 16:48 -
ASCO-GI preview: notable late-breakers
… 604 KRAS G12C inhibitor with solid tumour data at ESMO 2023 Defiance Leap Therapeutics DKN-01 + …
- 01/09/2024 - 11:43 -
Merck KGaA takes a punt on Inspirna’s novel approach
… with ompenaclid in second-line CRC Source: ESMO 2023. By way of benchmarks, Folfiri chemo …
- 01/05/2024 - 13:36 -
Bristol makes its radiopharma move
… data are expected late 2025 or early 2026 . At ESMO 2023, phase 1b data from that study found a 29% overall …
- 01/03/2024 - 17:27 -
More warnings signs for ATR inhibition
… ph1/2 +/- gemcitabine/irinotecan in solid tumours at ESMO 2023 IMP9064 Impact Therapeutics First data from ph1/2 +/- senaparib in solid tumours at ESMO 2023 Camonsertib Roche (licensed from Repare) …
- 11/14/2023 - 10:58 -
ESMO 2023 movers – who won and who lost?
ESMO 2023 movers – who won and who lost? …
- 12/14/2023 - 11:53 -
ESMO 2023 – BioNTech still has work to do on Claudin6
ESMO 2023 – BioNTech still has work to do on Claudin6 … trial +/- CARVac in CLDN6+ solid tumours (NCT04503278) ESMO 2023 with automated manufacturing: 45% ORR (17/38) …
- 07/10/2024 - 10:07 -
ESMO 2023 – Nectin-4 in focus
ESMO 2023 – Nectin-4 in focus Quick …
- 10/24/2023 - 14:58 -
ESMO 2023 – how datopotamab's lung side effects are graded
ESMO 2023 – how datopotamab's lung side effects are graded …
- 10/24/2023 - 14:57
